Syquant Capital Sas Acquires Shares of 92,010 Exact Sciences Corporation $EXAS

Syquant Capital Sas bought a new position in shares of Exact Sciences Corporation (NASDAQ:EXAS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 92,010 shares of the medical research company’s stock, valued at approximately $9,345,000. Exact Sciences makes up 1.1% of Syquant Capital Sas’ investment portfolio, making the stock its 13th largest holding.

Several other hedge funds also recently made changes to their positions in the business. Ameriprise Financial Inc. boosted its stake in shares of Exact Sciences by 105.8% in the third quarter. Ameriprise Financial Inc. now owns 4,493,085 shares of the medical research company’s stock valued at $245,802,000 after buying an additional 2,310,139 shares during the period. ARK Investment Management LLC increased its stake in Exact Sciences by 6,072,588.9% during the 3rd quarter. ARK Investment Management LLC now owns 2,186,168 shares of the medical research company’s stock worth $119,605,000 after acquiring an additional 2,186,132 shares during the period. Holocene Advisors LP raised its holdings in Exact Sciences by 189.5% in the 2nd quarter. Holocene Advisors LP now owns 2,145,181 shares of the medical research company’s stock valued at $113,995,000 after acquiring an additional 1,404,086 shares in the last quarter. Amova Asset Management Americas Inc. lifted its position in shares of Exact Sciences by 671.5% during the 3rd quarter. Amova Asset Management Americas Inc. now owns 1,286,595 shares of the medical research company’s stock valued at $70,390,000 after acquiring an additional 1,119,830 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Exact Sciences by 643.1% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,286,595 shares of the medical research company’s stock valued at $70,390,000 after acquiring an additional 1,113,459 shares during the period. 88.82% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on EXAS shares. Mizuho restated a “neutral” rating and issued a $105.00 price target (up from $85.00) on shares of Exact Sciences in a research report on Tuesday, January 20th. Zacks Research cut shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Exact Sciences in a research note on Thursday, January 22nd. Evercore set a $105.00 target price on shares of Exact Sciences and gave the company an “in-line” rating in a report on Monday, January 5th. Finally, BTIG Research restated a “neutral” rating on shares of Exact Sciences in a research report on Tuesday. Twenty-one equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Exact Sciences has a consensus rating of “Reduce” and a consensus price target of $92.13.

Exact Sciences Stock Performance

Shares of EXAS opened at $104.91 on Friday. Exact Sciences Corporation has a 52-week low of $38.81 and a 52-week high of $104.98. The business’s fifty day moving average is $103.27 and its 200-day moving average is $87.09. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.17 and a current ratio of 2.43. The firm has a market cap of $20.03 billion, a price-to-earnings ratio of -95.37, a PEG ratio of 2.02 and a beta of 1.41.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). The business had revenue of $878.38 million for the quarter, compared to analyst estimates of $860.59 million. Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.Exact Sciences’s quarterly revenue was up 23.1% on a year-over-year basis. During the same period last year, the firm posted ($0.06) EPS. Equities analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.